Information Provided By: 
Fly News Breaks for September 25, 2019
CHRS
Sep 25, 2019 | 05:38 EDT
August Symphony data show continued share gains for Coherus Biosciences' Udenyca, with total unit share now reaching 18.1%, up from 16.4% in July, Barclays analyst Balaji Prasad tells investors in a research note. The analyst believes Udenyca uptake "remains impressive" following Coherus' "strong" Q2 results. The stock remains his top pick with an Overweight rating and $31 price target.
News For CHRS From the Last 2 Days
There are no results for your query CHRS
